ALXO SEC-arkiveringar - ALX Oncology Holdings Inc.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

1810182

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ALX Oncology Holdings Inc.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

May 8, 2026	EX-99.1	ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update - Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD Exhibit 99.1 ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update - Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination - - Evorpacept data from two independent HER2-positive trials strengthens
May 8, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLO
May 8, 2026	EX-10.1	Re: Offer of Employment Appendix A Exhibit 10.1 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items February 24, 2026 Jeff Knight Via Email Re: Offer of Employment Dear Jeff: I am pleased to off
May 8, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2026 ALX ONCOLOGY HOLDINGS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2026 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission
April 20, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
April 20, 2026	ARS	ARS Annual ReportDear Fellow Shareholders, 2025 was a year of strong execution and meaningful scientific progress for ALX across both of our programs.
April 13, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2026 ALX ONCOLOGY HOLDI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2026 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi
April 13, 2026	EX-99.1	ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution Exhibit 99.1 ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) – ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnolo
March 9, 2026	EX-10.12	ALX ONCOLOGY HOLDINGS INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT Exhibit 10.12 ALX ONCOLOGY HOLDINGS INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made by and between ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), and (“Executive,” and together with the Company, the “Parties”), effective as of the Effective Date, as defined in Section 7 below, and amends and restates in it
March 9, 2026	EX-10.10	[Signature page follows] Exhibit 10.10 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items February 18, 2026 Barbara J. Klencke, M.D. Via Email Re: Offer of Employment Dear Barbara: I
March 9, 2026	10-K	Opinion on the Consolidated Financial Statements Basis for Opinion Critical Audit Matters UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HO
February 27, 2026	EX-99.1	ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains o Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months -
February 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2026 ALX ONCOLOGY HO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2026 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi
January 30, 2026	EX-99.1	New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - Exploratory analysis from Phase 1b/2 breast cancer trial reinforce EX-99.1 Exhibit 99.1 New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer - Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – - F
January 30, 2026	EX-1.1	76,979,112 Shares Pre-Funded Warrants to Purchase 18,574,120 Shares ALX Oncology Holdings Inc. UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 76,979,112 Shares and Pre-Funded Warrants to Purchase 18,574,120 Shares ALX Oncology Holdings Inc. UNDERWRITING AGREEMENT January 30, 2026 PIPER SANDLER & CO. UBS SECURITIES LLC WELLS FARGO SECURITIES, LLC As Representatives of the several Underwriters c/o PIPER SANDLER & CO. 350 North 5th Street, Suite 1000 Minneapolis, Minnesota 55401 c/o UBS SECURITIES LLC 11 Madison Avenue N
January 30, 2026	EX-4.1	ALX ONCOLOGY HOLDINGS INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK EX-4.1 Exhibit 4.1 ALX ONCOLOGY HOLDINGS INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: [•], 2026 ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitte
January 30, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2026 ALX ONCOLOGY HOL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2026 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis
January 30, 2026	EX-99.1	ALX Oncology Announces Pricing of Underwritten Offering EX-99.1 Exhibit 99.1 ALX Oncology Announces Pricing of Underwritten Offering SOUTH SAN FRANCISCO, Calif., January 30, 2026 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the pricing of an underwritten offering of common s
January 30, 2026	424B5	ALX ONCOLOGY HOLDINGS INC. 76,979,112 Shares of Common Stock Pre-Funded Warrants to Purchase 18,574,120 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-285620 Prospectus Supplement (To Prospectus Dated April 24, 2025) ALX ONCOLOGY HOLDINGS INC. 76,979,112 Shares of Common Stock Pre-Funded Warrants to Purchase 18,574,120 Shares of Common Stock We are offering 76,979,112 shares of our common stock, par value $0.001 per share (common stock) and, in lieu of common stock to
January 30, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2026 ALX ONCOLOGY HOL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2026 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis
January 21, 2026	S-8	As filed with the Securities and Exchange Commission on January 21, 2026 As filed with the Securities and Exchange Commission on January 21, 2026 Registration No.
January 21, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2026 ALX ONCOLOGY HOL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2026 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis
January 21, 2026	EX-FILING FEES	Calculation of Filing Fee Table Form S-8 (Form Type) ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001
January 21, 2026	EX-10.1	ALX ONCOLOGY HOLDINGS INC. 2025 INDUCEMENT EQUITY INCENTIVE PLAN Exhibit 10.1 ALX ONCOLOGY HOLDINGS INC. 2025 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose of the Plan. The purpose of this Plan is to attract and retain the best available personnel by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonstatutory Stock Options, Stock Appreciation Righ
November 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2025 ALX ONCOLOGY HOL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis
November 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ON
November 7, 2025	EX-99.1	ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update – ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients Exhibit 99.1 ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update – ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression – Phase 2 ASPEN-09-Breast Cancer trial remains on track for FPI in Q4 2025 and will evaluate evorpacept efficac
September 12, 2025	EX-99.1	ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer Exhibit 99.1 ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer – Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer – Alan Sandler, M.D. resigns as Chief Me
September 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2025 ALX ONCOLOGY H UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Comm
August 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 ALX ONCOLOGY HOLD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss
August 12, 2025	EX-99.1	ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be Exhibit 99.1 ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025 – Phase 2 ASPEN-Breast evorpacept trial design updated to enable CD47 and HER2 biomarker-dr
August 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLOG
June 12, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissio
May 8, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission
May 8, 2025	EX-10.1	Separation Agreement and Release between the Registrant and Jaume Pons, Ph.D. Exhibit 10.1 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items. ALX ONCOLOGY HOLDINGS INC. SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Rel
May 8, 2025	EX-10.2	Confirmatory Offer Letter between the Registrant and Alan Sandler, M.D. Exhibit 10.2 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items. November 10, 2024 Alan Sandler, M.D. Via Email Re: Offer of Employment Dear Alan: I am please
May 8, 2025	EX-10.3	Outside Director Compensation Policy. Exhibit 10.3 ALX ONCOLOGY HOLDINGS INC. OUTSIDE DIRECTOR COMPENSATION POLICY (as most recently amended and restated effective as of January 16, 2025 (the “Restatement Date”)) ALX Oncology Holdings Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents a powerful t
May 8, 2025	EX-99.1	ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update – Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to Exhibit 99.1 ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update – Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 – IND clearance received from U.S. FDA for novel EGFR-targeted a
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLO
April 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 ALX ONCOLOGY HOLDI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi
April 23, 2025	CORRESP	April 23, 2025 CORRESP Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O: 650.
April 21, 2025	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HOLDIN
April 21, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
March 11, 2025	LETTER	LETTER March 11, 2025 Jason Lettmann Chief Executive Officer ALX Oncology Holdings, Inc. 323 Allerton Avenue South San Francisco, CA 94080 Re: ALX Oncology Holdings, Inc. Registration Statement on Form S-3 Filed March 6, 2025 File No. 333-285620 Dear Jason Lettmann: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding
March 6, 2025	S-3	As filed with the Securities and Exchange Commission on March 6, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 6, 2025 Registration No.
March 6, 2025	EX-10.14	Separation Agreement and Release between the Registrant and Peter García. Exhibit 10.14 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items. ALX ONCOLOGY HOLDINGS INC. SEPARATION AGREEMENT AND MUTUAL RELEASE This Separation Agreement
March 6, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HO
March 6, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissio
March 6, 2025	EX-10.8	Confirmatory Offer Letter between the Registrant and Harish Shantharam. Exhibit 10.8 January 17, 2025 Harish Shantharam Via Email Re: Offer of Employment Dear Harish: I am pleased to offer you a position with ALX Oncology Holdings Inc. (the “Company”) in accordance with the terms of this Offer of Employment letter agreement (the “Agreement”). 1. Title; Position; Location. If you accept this offer of employment, you will serve as the Company’s Chief Financial Officer (
March 6, 2025	EX-21.1	List of subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES OF ALX ONCOLOGY HOLDINGS INC. Name of Subsidiary Jurisdiction of Incorporation or Organization ALX Oncology Limited Ireland ALX Oncology Incorporated Delaware
March 6, 2025	EX-19.1	Insider Trading Policy. Exhibit 19.1 ALX ONCOLOGY HOLDINGS INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities (Adopted and approved June 25, 2020 and effective as of the Company’s initial public offering, as amended on March 14, 2023) TABLE OF CONTENTS Page INTRODUCTION 1 Legal prohibitions on insider trading 1 Detection and prosecution of insider trading 1 Penalties for violati
March 6, 2025	EX-10.19	Outside Director Compensation Policy. Exhibit 10.19 ALX ONCOLOGY HOLDINGS INC. OUTSIDE DIRECTOR COMPENSATION POLICY (as most recently amended and restated effective as of January 16, 2025 (the “Restatement Date”)) ALX Oncology Holdings Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents a powerful
March 6, 2025	EX-10.11	Confirmatory Offer Letter between the Registrant and Alan Sandler, M.D. Exhibit 10.11 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items October 11, 2024 Alan Sandler, M.D. Via Email Re: Offer of Employment Dear Alan: I am pleased
March 6, 2025	EX-99.1	ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update – Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in pa Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update – Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI – Presented Phase 1b/2 data demonstrating evorpacept in
March 6, 2025	EX-FILING FEES	Filing Fee Table EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) ALX ONCOLOGY HOLDINGS INC.
March 5, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi
February 14, 2025	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of ALX Oncology Holdings, Inc. and further agree to the filing of this agreement as an exhibit
January 22, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 ALX ONCOLOGY HOL UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis
January 22, 2025	EX-99.1	ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors Exhibit 99.1 ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors - Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operations - Dr. Klencke is a se
January 17, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis
January 17, 2025	S-8	As filed with the Securities and Exchange Commission on January 17, 2025 S-8 1 d865005ds8.htm S-8 As filed with the Securities and Exchange Commission on January 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as specified in its charter) Delaware 85-0642577 (State or other jurisdiction of incorpora
January 17, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $
January 17, 2025	EX-10.1	2025 Inducement Equity Incentive Plan and forms of agreement thereunder. Exhibit 10.1 ALX ONCOLOGY HOLDINGS INC. 2025 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose of the Plan. The purpose of this Plan is to attract and retain the best available personnel by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonstatutory Stock Options, Stock Appreciation Righ
January 17, 2025	EX-4.3	2025 Inducement Equity Incentive Plan and forms of agreement thereunder. Exhibit 4.3 ALX ONCOLOGY HOLDINGS INC. 2025 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose of the Plan. The purpose of this Plan is to attract and retain the best available personnel by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonstatutory Stock Options, Stock Appreciation Right
December 31, 2024	SC TO-I/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ALX ONCOLOGY HOLDINGS INC. (Name of Subject Compa SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ALX ONCOLOGY HOLDINGS INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.001 par value (Title of Class of Securities) 00166B105 (CUSIP
December 6, 2024	EX-99	EX-99 Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.
December 2, 2024	EX-99.(A)(1)(C)	Form of Eligible Option Schedule. Exhibit (a)(1)(C) Eligible Option Grant Schedule ALX Oncology Holdings Inc. ID: 85-642577 323 Allerton Avenue South San Francisco, California 94080 AS OF DECEMBER 2, 2024 [Name] Employee ID: [Number] [Address] ELIGIBLE OPTION GRANT NEW OPTION GRANT Grant Date Grant Number Exercise Price Per Share Type of Eligible Option Grant (ISO / NSO) Number of Vested Shares Subject to Eligible Option Grant Thr
December 2, 2024	EX-99.(A)(1)(F)	Form of Reminder Email. Exhibit (a)(1)(F) Form of Reminder Email The ALX Oncology Holdings Inc. (“ALX”) offer to exchange certain outstanding stock options for new stock options (referred to as the “Offer”) currently is still open. Please note that the Offer will expire at 9:00 p.m., Pacific Time, on December 30, 2024, unless we extend the Offer. The Offer deadline will be strictly enforced, so we encourage you to give y
December 2, 2024	EX-99.(A)(1)(B)	Launch Announcement. Exhibit (a)(1)(B) EMAIL TO ALL ELIGIBLE EMPLOYEES From: optionexchange@alxoncology.
December 2, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filling Fee Tables Schedule TO (Form Type) ALX Oncology Holdings Inc.
December 2, 2024	EX-99.(A)(1)(A)	Offer to Exchange Certain Outstanding Stock Options for New Stock Options, dated December 2, 2024. Exhibit (a)(1)(A) ALX ONCOLOGY HOLDINGS INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS This document constitutes part of the prospectus relating to the securities that have been registered under the Securities Act of 1933, as amended. The prospectus relates to the ALX Oncology Holdings Inc. Amended and Restated 2020 Equity Incentive Plan. December 2, 2024 ALX ONCOLO
December 2, 2024	SC TO-I	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ALX ONCOLOGY HOLDINGS INC. (Name of Subject Company (Issuer) and Fili UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ALX ONCOLOGY HOLDINGS INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.001 par value (Title of Class of Securities) 00166B105 (CUSIP Number of Class of Securities’
December 2, 2024	EX-99.(A)(1)(D)	Election Form. Exhibit (a)(1)(D) ALX ONCOLOGY HOLDINGS INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS ELECTION FORM THE OFFER EXPIRES AT 9:00 P.M., PACIFIC TIME, ON DECEMBER 30, 2024, UNLESS THE OFFER IS EXTENDED Terms used in this Election Form, including the Election Terms & Conditions and Election Instructions attached hereto, that are defined in the Offer to Exchange have the
December 2, 2024	EX-99.(A)(1)(H)	Form of Expiration Notice Email. Exhibit (a)(1)(H) Form of Notice to Eligible Employees Regarding Expiration of Offering Period To: Eligible Employees From: optionexchange@alxoncology.
December 2, 2024	EX-99.(A)(1)(G)	Form of Notice Email Announcing Final Offer Terms. Exhibit (a)(1)(G) Form of Notice Email Announcing Final Offer Terms To: Eligible Employees From: Jason Lettmann, Chief Executive Officer, ALX Oncology Holdings Inc.
December 2, 2024	EX-99.(A)(1)(E)	Form of Confirmation Email. Exhibit (a)(1)(E) Form of Confirmation to Eligible Employees ALX Oncology Holdings Inc.
November 14, 2024	EX-99.1	Joint Filing Statement EX-99.1 2 ea022116103ex99-1alxon.htm JOINT FILING STATEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint f
November 14, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis
November 14, 2024	SC 13G/A	ALXO / ALX Oncology Holdings Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 cormorant-alxo093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ALX ONCOLOGY HOLDINGS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00166B105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
November 14, 2024	EX-99.1	ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer Exhibit 99.1 ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development SOUTH SAN FRANCISCO, Calif., November 14, 2024 - ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune s
November 14, 2024	SC 13G/A	ALXO / ALX Oncology Holdings Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 ss4113341sc13ga.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00166B105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stat
November 14, 2024	SC 13G/A	ALXO / ALX Oncology Holdings Inc. / Vivo Capital Fund IX, L.P. - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea022116103-13ga1viv9alxon.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ALX Oncology Holdings Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) September 30, 2024 (Date of Event whi
November 12, 2024	SC 13G/A	ALXO / ALX Oncology Holdings Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 ALX ONCOLOGY HOLDINGS INC COMMON STOCK Cusip #00166B105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00166B105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,856,668 Item 6: 0 Item 7: 5,865,106 Item 8: 0 I
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ON
November 7, 2024	EX-99.1	ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., November 7, 2024 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today report
November 7, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis
November 7, 2024	EX-10.1	Separation Agreement and Release between the Registrant and Sophia Randolph, M.D., Ph.D. Exhibit 10.1 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items. ALX ONCOLOGY HOLDINGS INC. SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Rel
October 10, 2024	SC 13G/A	ALXO / ALX Oncology Holdings Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ALX ONCOLOGY HOLDINGS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 00166B105 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate
October 4, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Comm
August 22, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of ALX Oncology Holdings Inc. and further agree to the filing
August 22, 2024	SC 13G	ALXO / ALX Oncology Holdings Inc. / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
August 13, 2024	SC 13G	ALXO / ALX Oncology Holdings Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ALX ONCOLOGY HOLDINGS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 00166B105 (CUSIP Number) AUGUST 6, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to w
August 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLOG
August 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi
August 8, 2024	EX-99.1	ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., August 8, 2024 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended
August 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 ALX ONCOLOGY HOLDI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi
August 6, 2024	EX-99.1	ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors ▪ Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development – ▪ Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., will leave board to focus o Exhibit 99.1 ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors ▪ Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development – ▪ Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., will leave board to focus on ALX leadership responsibilities as Company’s clinical program advances – SOUTH SAN FRANCISCO, Calif., August 6, 2024 (GLOBE NEWSWIRE) -
June 17, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissio
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLO
May 9, 2024	EX-99.1	ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., May 9, 2024 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission
May 2, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi
May 2, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. __) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 23, 2024	ARS	ARS
April 22, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
March 8, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0
March 8, 2024	S-8	As filed with the Securities and Exchange Commission on March 7, 2024 As filed with the Securities and Exchange Commission on March 7, 2024 Registration No.
March 7, 2024	EX-4.3	Description of Securities. Exhibit 4.3 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The authorized capital stock of ALX Oncology Holdings Inc., consists of 1,000,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of convertible preferred stock, par value $0.001 per share. We have one class of securities registered under Sectio
March 7, 2024	EX-97.1	Compensation Recovery Policy. Exhibit 97.1 ALX ONCOLOGY HOLDINGS INC. COMPENSATION RECOVERY POLICY As adopted on July 25, 2023 ALX Oncology Holdings Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”) pursuant to approval by the Compensation Committee (the “Committee”) of the Company’s B
March 7, 2024	EX-99.1	ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., March 7, 2024 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth q
March 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissio
March 7, 2024	EX-21.1	List of subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES OF ALX ONCOLOGY HOLDINGS INC. Name of Subsidiary Jurisdiction of Incorporation or Organization ALX Oncology Limited Ireland ALX Oncology Incorporated Delaware Alexo International Holdings Limited Malta
March 7, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HO
February 14, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 tm245846d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock of ALX Onc
February 14, 2024	SC 13D/A	ALXO / ALX Oncology Holdings Inc. / LSV Associates, LLC - SC 13D/A Activist Investment SC 13D/A 1 tm246244d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) Travis Boettner Lightstone Ventures 500 Boylston St. Suite 1380 Boston,
February 14, 2024	SC 13G/A	ALXO / ALX Oncology Holdings Inc. / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245846d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement)
February 14, 2024	EX-99.A	JOINT FILING AGREEMENT EX-99.A 2 ss30005514ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. 1 to the Statement on Schedule 13G, dated December 31, 2023 (this “Schedule 13G”), with respect to the Common Stock, $0.001 par value per share, of ALX Oncology Holdings Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of
February 14, 2024	SC 13G/A	ALXO / ALX Oncology Holdings Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 9, 2024	SC 13G/A	ALXO / ALX Oncology Holdings Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No.3 ALX ONCOLOGY HOLDINGS INC COMMON STOCK Cusip #00166B105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00166B105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,471,685 Item 6: 0 Item 7: 7,472,821 Item 8: 0 Item 9: 7,472,821 Item
December 26, 2023	EX-10.1	Third Amendment to Loan and Security Agreement, dated as of December 22, 2023, among Oxford Finance LLC, as collateral agent, the lenders party thereto, ALX Oncology Inc., as borrower, and ALX Oncology Holdings Inc., as guarantor. Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of December 22, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the
December 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 ALX ONCOLOGY HO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi
December 20, 2023	SC 13D/A	ALXO / ALX Oncology Holdings Inc. / LSV Associates, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) Travis Boettner Lightstone Ventures 500 Boylston St. Suite 1380 Boston, MA 02116 (617) 933-3770 (Name, Address an
November 13, 2023	EX-10.1	Amendment No. 1 to the Sales Agreement with Cantor and Credit Suisse, dated August 25, 2023. Exhibit 10.1 [***] = Pursuant to Item 601(b)(10) of Regulation S-K, certain information contained in this document, marked by brackets, has been omitted because it is both not material and is the type of information that the registrant treats as private or confidential. ALX ONCOLOGY HOLDINGS INC. AMENDMENT NO. 1 TO THE SALES AGREEMENT August 25, 2023 Cantor Fitzgerald & Co. 110 E 59th Steet, 6th F
November 13, 2023	EX-99.1	ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., November 13, 2023 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the third quarter ended
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 ALX ONCOLOGY HO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ON
October 16, 2023	SC 13G	ALXO / Alx Oncology Holdings Inc / Redmile Group, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) October 4, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
October 16, 2023	EX-99.1	Joint Filing Agreement EX-99.1 2 tm2328366d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock of ALX On
October 13, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of October 13, 2023, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC Cormorant Asset Management, LP and Bihua
October 13, 2023	SC 13G	ALXO / Alx Oncology Holdings Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ALX Oncology Holdings Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00166B105 (CUSIP Number) October 3, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
October 6, 2023	424B5	7,370,690 Shares of Common Stock Pre-Funded Warrants to Purchase 1,250,000 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263863 Prospectus Supplement (To Prospectus Dated May 25, 2022) 7,370,690 Shares of Common Stock Pre-Funded Warrants to Purchase 1,250,000 Shares of Common Stock We are offering 7,370,690 shares of our common stock, par value $0.001 per share (common stock) and, in lieu of common stock to certain investors, pre-funded wa
October 6, 2023	EX-4.1	Form of Pre-Funded Warrant. EX-4.1 Exhibit 4.1 ALX ONCOLOGY HOLDINGS INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: [], 2023 ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered
October 6, 2023	EX-99.1	ALX Oncology Announces Pricing of Public Offering EX-99.1 Exhibit 99.1 ALX Oncology Announces Pricing of Public Offering SOUTH SAN FRANCISCO, Calif., October 5, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the pricing of its previously announced underwritten public offering of comm
October 6, 2023	EX-1.1	Underwriting Agreement, dated as October 4, 2023, among ALX Oncology Holdings Inc. and the Representatives. EX-1.1 Exhibit 1.1 7,370,690 Shares and Pre-Funded Warrants to Purchase 1,250,000 Shares ALX Oncology Holdings Inc. UNDERWRITING AGREEMENT October 4, 2023 PIPER SANDLER & CO. CANTOR FITZGERALD & CO. As Representatives of the several Underwriters c/o PIPER SANDLER & CO. 1251 Avenue of the Americas, 6th Floor New York, New York 10020 c/o CANTOR FITZGERALD & CO. 110 E. 59th St., 6th Floor New York, N
October 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 ALX ONCOLOGY HOLD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss
October 4, 2023	424B5	Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263863 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell
October 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 ALX ONCOLOGY HOLD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss
October 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 ALX ONCOLOGY HOLD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss
October 4, 2023	EX-99.1	ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer — Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumor Exhibit 99.1 ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer — Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors — Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for
September 8, 2023	424B3	18,446,936 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-274314 PROSPECTUS 18,446,936 Shares of Common Stock This prospectus relates to the proposed resale or other disposition from time to time of up to 18,446,936 shares of our common stock, par value $0.001 per share by the selling stockholders identified in this prospectus, including their transferees, pledgees, donees or other s
September 7, 2023	CORRESP	September 7, 2023 Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O: 650.
September 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 ALX ONCOLOGY HO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi
September 6, 2023	EX-99.1	ALX Oncology Realigns Executive Leadership Team - Jason Lettmann appointed as Chief Executive Officer - Dr. Jaume Pons transitions to Chief Scientific Officer EX-99.1 Exhibit 99.1 ALX Oncology Realigns Executive Leadership Team - Jason Lettmann appointed as Chief Executive Officer - Dr. Jaume Pons transitions to Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., September 6, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune c
September 6, 2023	LETTER	LETTER United States securities and exchange commission logo September 6, 2023 Jaume Pons, Ph.
September 6, 2023	EX-10.2	Confirmatory Employment Letter between the Registrant and Jaume Pons, Ph.D. EX-10.2 Exhibit 10.2 323 Allerton Avenue South San Francisco, California Phone: (650) 466-7125 September 5, 2023 Jaume Pons, Ph.D. Via Email Re: Confirmatory Employment Letter Dear Jaume: This confirmatory employment letter agreement (the “Agreement”) is entered into between Jaume Pons (“you”) and ALX Oncology Holdings Inc. (the “Company” or “we”), effective as of September 6, 2023 (the “Effective
September 6, 2023	EX-10.1	Confirmatory Employment Letter between the Registrant and Jason Lettmann. EX-10.1 Exhibit 10.1 323 Allerton Avenue South San Francisco, California Phone: (650) 466-7125 September 5, 2023 Jason Lettmann Via Email Re: Offer of Employment Dear Jason: I am pleased to offer you a position with ALX Oncology Holdings Inc. (the “Company”) in accordance with the terms of this Offer of Employment letter agreement (the “Agreement”). 1. Title; Position; Location. If you accept this
September 1, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) ALX Oncology Holdings Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees
September 1, 2023	S-3	As filed with the Securities and Exchange Commission on September 1, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on September 1, 2023 Registration No.
August 25, 2023	424B5	Up to $150,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration Number 333-263863 Supplement dated August 25, 2023 To Prospectus Supplement dated May 25, 2022 (To Prospectus dated May 25, 2022) Up to $150,000,000 Common Stock This supplement, or Supplement, updates, amends and supplements the prospectus supplement, dated May 25, 2022, or Prospectus Supplement, relating to the offer and sale of shares of common stock, par value $0.
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLOG
August 10, 2023	EX-10.1	Second Amendment to Loan and Security Agreement, dated as of May 31, 2023. Exhibit 10.1 [***] = Pursuant to Item 601(b)(10) of Regulation S-K, certain information contained in this document, marked by brackets, has been omitted because it is both not material and is the type of information that the registrant treats as private or confidential. SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entere
August 10, 2023	EX-99.1	ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update Advancing Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423 Terminating azacitidine combination development programs: ASPEN-02 in Exhibit 99.1 ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update Advancing Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423 Terminating azacitidine combination development programs: ASPEN-02 in MDS and ASPEN-05 in AML Continuing focus on combinations with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune che
August 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 ALX ONCOLOGY HOLD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss
June 20, 2023	EX-3.1	Amended and Restated Bylaws of the Registrant. Exhibit 3.1 ALX ONCOLOGY HOLDINGS INC. AMENDED AND RESTATED BYLAWS (initially adopted on April 1, 2020) (as amended effective on June 17, 2023) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOC
June 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 ALX ONCOLOGY HOLDIN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissio
May 11, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission
May 11, 2023	EX-10.1	Outside Director Compensation Policy. ALX ONCOLOGY HOLDINGS INC. OUTSIDE DIRECTOR COMPENSATION POLICY (as amended and restated effective as of March 14, 2023 (the “Restatement Date”)) ALX Oncology Holdings Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents a powerful tool to attract, retain and re
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLO
May 11, 2023	EX-99	ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Exhibit 99.1 ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fir
April 24, 2023	ARS	ARS ANNUAL R E P P O R T T 2 20 022 April 24, 2023 To Our Shareholders, 2022 was another productive year for ALX Oncology.
April 24, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ALX ONCOLOGY HOLDI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi
March 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 ALX ONCOLOGY HOLDIN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissio
March 9, 2023	EX-99	ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones SOUTH SAN FRANCISCO, Calif., March 9, 2023 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, toda
March 9, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0
March 9, 2023	EX-21	List of subsidiaries of Registrant. SUBSIDIARIES OF ALX ONCOLOGY HOLDINGS INC. Name of Subsidiary Jurisdiction of Incorporation or Organization ALX Oncology Limited Ireland ALX Oncology Incorporated Delaware Alexo International Holdings Limited Malta
March 9, 2023	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HO
March 9, 2023	EX-10	Consent and First Amendment to Loan and Security Agreement, dated as of December 22, 2022. Exhibit 10.1.1 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items. CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND FIRST AMENDMENT
March 9, 2023	S-8	Power of Attorney (contained on signature page hereto). S-8 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No.
March 9, 2023	EX-4	Description of Securities. Exhibit 4.3 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The authorized capital stock of ALX Oncology Holdings Inc., consists of 1,000,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of convertible preferred stock, par value $0.001 per share. We have one class of securities registered under Sectio
February 14, 2023	SC 13G	ALXO / ALX Oncology Holdings Inc / ORBIMED ADVISORS LLC - SCHEDULE 13G Passive Investment SC 13G 1 ss1758552sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00166B105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria
February 14, 2023	EX-99.A	JOINT FILING AGREEMENT EX-99.A 2 ss1758552ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated December 31, 2022 (the “Schedule 13G”), with respect to the Common Stock, $0.001 par value per share, of ALX Oncology Holdings Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under th
February 9, 2023	SC 13G/A	ALXO / ALX Oncology Holdings Inc / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 ALX ONCOLOGY HOLDINGS INC COMMON STOCK Cusip #00166B105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00166B105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,113,159 Item 6: 0 Item 7: 6,113,428 Item 8: 0 I
November 29, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi
November 29, 2022	EX-99.1	ALX Oncology Appoints Scott Garland to its Board of Directors Exhibit 99.1 ALX Oncology Appoints Scott Garland to its Board of Directors SOUTH SAN FRANCISCO, Calif., November 29, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Scott Garland to its Board of Directors (the ?Board?) effectiv
November 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ON
November 8, 2022	EX-99.1	ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Exhibit 99.1 ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., November 8, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the
October 31, 2022	EX-99.1	ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept Expects to extend cash runway to mid-2025 Exhibit 99.1 ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept Expects to extend cash runway to mid-2025 SOUTH SAN FRANCISCO, Calif., October 31, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block t
October 31, 2022	EX-10.1	Loan and Security Agreement, dated as of October 27, 2022, among Oxford Finance LLC, as collateral agent, the lenders from time to time party thereto, ALX Oncology Inc., Alexo Therapeutics International, and Sirpant Therapeutics, each as a borrower, and ALX Oncology Holdings Inc., as guarantor. Exhibit 10.1 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items. [***] = Pursuant to Item 601(b)(10) of Regulation S-K, certain information contained in this
October 31, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis
August 10, 2022	SC 13G/A	ALXO / ALX Oncology Holdings Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No.1 ALX ONCOLOGY HOLDINGS INC COMMON STOCK Cusip #00166B105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00166B105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,279,681 Item 6: 0 Item 7: 4,280,516 Item 8: 0 Item 9: 4,280,516 Item
August 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLOG
August 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi
August 8, 2022	EX-99.1	ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Exhibit 99.1 ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., August 8, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the s
June 16, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-39386 85-0642577 (State or other jurisdiction of incorporation) (Commissio
June 10, 2022	SC 13G/A	ALXO / ALX Oncology Holdings Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ALX ONCOLOGY HOLDINGS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00166B105 (CUSIP Number) May 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
May 31, 2022	EFFECT	EFFECT X0101 EFFECT 33 LIVE 2022-05-31 0001193125-22-162411 POS AM 0001810182 ALX ONCOLOGY HOLDINGS INC 333-258812
May 27, 2022	POS AM	As filed with the U.S. Securities and Exchange Commission on May 27, 2022 As filed with the U.S. Securities and Exchange Commission on May 27, 2022 Registration No. 333-258812 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as specified in its charter) Delaware 85-0642577 (State or other jurisdict
May 24, 2022	CORRESP	May 24, 2022 Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O: 650.
May 13, 2022	S-3/A	As filed with the Securities and Exchange Commission on May 13, 2022 Table of Contents As filed with the Securities and Exchange Commission on May 13, 2022 Registration No.
May 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLO
May 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission
May 9, 2022	EX-99.1	ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Exhibit 99.1 ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., May 9, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first
April 22, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 12, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi
April 12, 2022	EX-99.1	ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors Exhibit 99.1 ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors (th
March 29, 2022	LETTER	LETTER United States securities and exchange commission logo March 29, 2022 Jaume Pons, Ph.
March 25, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Table Form S-3 (Form Type) ALX Oncology Holdings Inc. (Exact name of registrant as specified in its charter) Table 1 ? Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registratio
March 25, 2022	S-3	Form S-3 Table of Contents As filed with the Securities and Exchange Commission on March 25, 2022 Registration No.
February 28, 2022	EX-99.1	ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today
February 28, 2022	S-8	As filed with the Securities and Exchange Commission on February 28, 2022 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No.
February 28, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0
February 28, 2022	EX-4.3	Description of Securities. Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The authorized capital stock of ALX Oncology Holdings Inc., consists of 1,000,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of convertible preferred stock, par value $0.001 per share. We have one class of securities registered under Sectio
February 28, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HO
February 28, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi
February 28, 2022	EX-10.6	Confirmatory Offer Letter between the Registrant and Shelly Pinto. Exhibit 10.6 866 Malcolm Road, Suite 100 Burlingame, CA 94010 Phone: (650) 466-7125 May 3, 2021 Shelly Pinto Via Email Re: Confirmatory Employment Letter Dear Shelly: This confirmatory employment letter agreement (the ?Agreement?) is entered into between Shelly Pinto (?you?) and ALX Oncology Holdings Inc. (the ?Company? or ?we?), effective as of May 3, 2021 (the ?Effective Date?), to confirm the t
February 28, 2022	EX-21.1	List of subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES OF ALX ONCOLOGY HOLDINGS INC. Name of Subsidiary Jurisdiction of Incorporation or Organization ALX Oncology Limited Ireland ALX Oncology Incorporated Delaware Alexo Holding Limited Malta Alexo Therapeutics International Cayman Islands Sirpant Therapeutics Cayman Islands ScalmiBio, Inc. Delaware
February 9, 2022	SC 13G	ALXO / ALX Oncology Holdings Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 0 ALX ONCOLOGY HOLDINGS INC COMMON STOCK Cusip #00166B105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00166B105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 81,786 Item 6: 0 Item 7: 2,592,939 Item 8: 0 Item 9: 2,592,939 Item 11
February 4, 2022	SC 13G/A	ALXO / ALX Oncology Holdings Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ALX ONCOLOGY HOLDINGS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00166B105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
December 17, 2021	EX-1.1	Sales Agreement, dated as of December 17, 2021, between the Registrant, Cantor Fitzgerald & Co. and Credit Suisse Securities (USA) LLC Exhibit 1.1 Execution Version ALX ONCOLOGY HOLDINGS INC. Shares of Common Stock (par value $0.001 per share) Sales Agreement December 17, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010 Ladies and Gentlemen: ALX Oncology Holdings Inc., a Delaware corporation (the ?Company?), confirms its agreement (th
December 17, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-39386 85-0642577 (State or other jurisdiction of incorporation) (Commi
December 17, 2021	424B5	CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee (1) Common stock, par value $0.001 per share $150,000,000 $13,905 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-258812 CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee (1) Common stock, par value $0.
November 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39386 ALX ONCOLOGY HOLDINGS INC.
November 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi
November 12, 2021	EX-99.1	ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Exhibit 99.1 ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., November 11, 2021 - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter en
October 7, 2021	EX-99.1	ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio Exhibit 99.1 ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio ? Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cytotoxic payloads for antibody drug conjugates ? Expands ALX Oncology?s pipeline of drug candidates based on expertise in protein engineering and oncology SOUTH SAN F
October 7, 2021	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss
September 10, 2021	SC 13G	ALXO / ALX Oncology Holdings Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ALX ONCOLOGY HOLDINGS INC (Name of Issuer) Common Stock (Title of Class of Securities) 00166B105 (CUSIP Number) August 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
August 27, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss
August 13, 2021	S-3ASR	Registration Statement on Form S-3 Table of Contents As filed with the Securities and Exchange Commission on August 13, 2021 Registration No.
August 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39386 ALX ONCOLOGY HOLDINGS INC.
August 12, 2021	EX-99.1	ALX ONCOLOGY HOLDINGS INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) Exhibit 99.1 ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights BURLINGAME, Calif., August 12, 2021 - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June
June 15, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) Virginia Yee Logos Global Management LP One Letterman Drive, Building D, Suite D3-700 San Francisco, CA 94129 Tele
June 15, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-39386 85-0642577 (State or other jurisdiction of incorporation) (Commissio
May 17, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission
May 17, 2021	EX-99.1	ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Exhibit 99.1 ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights BURLINGAME, Calif., May 17, 2021 - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31,
May 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39386 ALX ONCOLOGY HOLDINGS INC.
May 4, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission
April 29, 2021	DEF 14A	definitive proxy statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi
March 25, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi
March 18, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 18, 2021 Registration No.
March 18, 2021	EX-4.3	Description of Securities. Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The authorized capital stock of ALX Oncology Holdings Inc., consists of 1,000,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of convertible preferred stock, par value $0.001 per share. We have one class of securities registered under Sectio
March 18, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi
March 18, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HO
March 18, 2021	EX-99.1	ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones BURLINGAME, Calif., March 18, 2021 - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial resul
March 15, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction (Commission (IRS Employer o
March 15, 2021	EX-99.1	ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors EX-99.1 Exhibit 99.1 ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors BURLINGAME, Calif., March 15, 2021 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Sophia Randolph, M.D., Ph.D., to its
December 23, 2020	8-K	- 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2020 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction (Commission (IRS Emp
December 11, 2020	424B4	2,380,000 Shares Common Stock 424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration Nos. 333-251171 and 333-251248 PROSPECTUS 2,380,000 Shares Common Stock We are offering 2,380,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “ALXO.” On December 9, 2020, the last reported sale price of our common stock on the Nasdaq Global Select Market was $81.73 p
December 10, 2020	S-1MEF	- S-1MEF S-1MEF As filed with the Securities and Exchange Commission on December 9, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as specified in its charter) Delaware 2834 85-0642577 (State or other jurisdiction of incorporation or orga
December 7, 2020	S-1	Registration Statement - S-1 S-1 Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on December 7, 2020 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
December 7, 2020	CORRESP	December 7, 2020 December 7, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
December 7, 2020	EX-1.1	Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 [●] Shares ALX Oncology Holdings Inc. UNDERWRITING AGREEMENT [●], 2020 JEFFERIES LLC CREDIT SUISSE SECURITIES (USA) LLC PIPER SANDLER & CO. CANTOR FITZGERALD & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o CREDIT SUISSE SECURITIES (USA) LLC Eleven Madison Avenue New York, New York 10010 c/o PIPER SANDLER & CO
December 7, 2020	CORRESP	[signature page follows] December 7, 2020 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
November 25, 2020	LETTER	LETTER United States securities and exchange commission logo November 25, 2020 Jaume Pons, Ph.
November 24, 2020	DRS	- Draft Registration Statement Table of Contents Index to Financial Statements Confidential Treatment Requested by ALX Oncology Holdings Inc.
November 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi
November 12, 2020	EX-99.1	ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights Exhibit 99.1 ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights BURLINGAME, Calif., November 12, 2020 - ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter ended Septe

ALXO / ALX Oncology Holdings Inc. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?